Design, Synthesis and Biological Evaluation of Novel Piperazine Derivatives as CCR5 Antagonists

By using a fragment-assembly strategy and bioisosteric-replacement principle, a series of novel piperazine derivatives were designed, synthesized, and evaluated for their cellular target-effector fusion activities and in vitro antiviral activities against HIV-1. Preliminary structure-activity relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tao, Weng, Zhiyong, Dong, Xiaowu, Chen, Linjie, Ma, Ling, Cen, Shan, Zhou, Naiming, Hu, Yongzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538727/
https://www.ncbi.nlm.nih.gov/pubmed/23308267
http://dx.doi.org/10.1371/journal.pone.0053636
Descripción
Sumario:By using a fragment-assembly strategy and bioisosteric-replacement principle, a series of novel piperazine derivatives were designed, synthesized, and evaluated for their cellular target-effector fusion activities and in vitro antiviral activities against HIV-1. Preliminary structure-activity relationships (SARs) of target compounds were concluded in this study, and five compounds were found to exhibited medium to potent CCR5 fusion activities with IC(50) values in low micromolar level. Among evaluated compounds, 23 h was found to be a CCR5 antagonist with an IC(50) value of 6.29 µM and an anti-HIV-1 inhibitor with an IC(50) value of 0.44 µM.

Ejemplares similares